Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for NuCana PLC Sponsored ADR (NCNA : NSDQ)
 
 • Company Description   
NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom.

Number of Employees: 29

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.60 Daily Weekly Monthly
20 Day Moving Average: 208,351 shares
Shares Outstanding: 52.18 (millions)
Market Capitalization: $31.31 (millions)
Beta: 0.58
52 Week High: $3.40
52 Week Low: $0.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.15% -29.22%
12 Week -78.26% -76.10%
Year To Date -74.79% -69.20%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3 Lochside Way
-
Edinburgh,X0 EH12 9DT
GBR
ph: 44-0-13-1357-1111
fax: -
chris.brinzey@westwicke.com http://www.nucana.com
 
 • General Corporate Information   
Officers
Hugh Griffith - Chief Executive Officer
Andrew Kay - Chairman
Donald Munoz - Chief Financial Officer
Martin Mellish - Director
Adam George - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67022C106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/18/22
Share - Related Items
Shares Outstanding: 52.18
Most Recent Split Date: (:1)
Beta: 0.58
Market Capitalization: $31.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/18/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.35
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -9.38%
vs. Previous Quarter: -66.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -50.49
09/30/21 - -44.72
ROA
03/31/22 - -
12/31/21 - -44.64
09/30/21 - -40.30
Current Ratio
03/31/22 - -
12/31/21 - 6.11
09/30/21 - 6.72
Quick Ratio
03/31/22 - -
12/31/21 - 6.11
09/30/21 - 6.72
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 1.73
09/30/21 - 2.05
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©